{"disease":{"id":"natural-killer-t-cell-lymphoma-nasal-and-nasal-type","name":"natural killer t cell lymphoma nasal and nasal type"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06314334","title":"Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06583083","title":"Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03623087","title":"SIMPLE Chemotherapy for NK Lymphoma/Leukaemia","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":68,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT05058755","title":"Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04366128","title":"Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Rong Tao","has_results":false},{"nct_id":"NCT03936452","title":"Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06376721","title":"Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT04004572","title":"Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":37,"lead_sponsor_name":"Rong Tao","has_results":false},{"nct_id":"NCT03618238","title":"Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}